These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23342816)

  • 1. Racial/Ethnic composition of study participants in FDA-approved oncology new molecular entities, 2006-2008.
    Merenda C
    J Natl Med Assoc; 2012; 104(9-10):430-5. PubMed ID: 23342816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.
    Evelyn B; Toigo T; Banks D; Pohl D; Gray K; Robins B; Ernat J
    J Natl Med Assoc; 2001 Dec; 93(12 Suppl):18S-24S. PubMed ID: 11798060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
    Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
    Trials; 2016 Apr; 17():199. PubMed ID: 27079511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Evaluation of Novel Oncology Approvals with a PMR/C for Assessing Data in Racial and Ethnic Populations Underrepresented in Premarket Clinical Trials.
    Collins G; Andrews HS; McKelvey B; Rice C; Allen JD; Stewart MD
    Clin Cancer Res; 2024 Aug; 30(16):3388-3394. PubMed ID: 38884580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.
    Ramamoorthy A; Knepper TC; Merenda C; Mendoza M; McLeod HL; Bull J; Zhang L; Pacanowski M
    Clin Pharmacol Ther; 2018 Nov; 104(5):940-948. PubMed ID: 30218447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. racial and ethnic participation in global clinical trials by therapeutic areas.
    Lolic M; Araojo R; Okeke M; Temple R
    J Clin Pharm Ther; 2021 Dec; 46(6):1576-1581. PubMed ID: 34544200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
    Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
    J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
    Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
    Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies.
    Aldrighetti CM; Niemierko A; Van Allen E; Willers H; Kamran SC
    JAMA Netw Open; 2021 Nov; 4(11):e2133205. PubMed ID: 34748007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
    Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
    J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
    Berkowitz ST; Groth SL; Gangaputra S; Patel S
    JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020.
    Lythgoe MP; Krell J; Savage P; Prasad V
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1208-1211. PubMed ID: 33859363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender and Ethnicity of Enrolled Participants in U.S. Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities.
    Birnbaum FA
    J Natl Med Assoc; 2018 Oct; 110(5):473-479. PubMed ID: 30129511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors.
    Yekedüz E; Trapani D; Xu W; de Vries EGE; Labaki C; Gyawali B; Gulati S; Nabhan C; Utkan G; Curigliano G; Choueiri TK; Ürün Y
    Int J Cancer; 2021 Oct; 149(7):1455-1462. PubMed ID: 34124786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
    Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
    J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
    Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
    Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.